Literature DB >> 18630894

Slow self-activation enhances the potency of viridin prodrugs.

Joseph Blois1, Hushan Yuan, Adam Smith, Michael E Pacold, Ralph Weissleder, Lewis C Cantley, Lee Josephson.   

Abstract

When the viridin wortmannin (Wm) is modified by reaction with certain nucleophiles at the C20 position, the compounds obtained exhibit an improved antiproliferative activity even though a covalent reaction between C20 and a lysine in the active site of PI3 kinase is essential to Wm's ability to inhibit this enzyme. Here we show that this improved potency results from an intramolecular attack by the C6 hydroxyl group that slowly converts these inactive prodrugs to the active species Wm over the 48 h duration of the antiproliferative assay. Our results provide a guide for selecting Wm-like compounds to maximize kinase inhibition with the variety of protocols used to assess the role of PI3 kinase in biological systems, or for achieving optimal therapeutic effects in vivo . In addition, the slow self-activation of WmC20 derivatives provides a mechanism that can be exploited to obtain kinase inhibitors endowed with physical and pharmacokinetic properties far different from man-made kinase inhibitors because they do not bind to kinase active sites.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18630894      PMCID: PMC2663427          DOI: 10.1021/jm800374f

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  37 in total

1.  Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction.

Authors:  M P Wymann; G Bulgarelli-Leva; M J Zvelebil; L Pirola; B Vanhaesebroeck; M D Waterfield; G Panayotou
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

2.  DNA-dependent protein kinase catalytic subunit: a relative of phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product.

Authors:  K O Hartley; D Gell; G C Smith; H Zhang; N Divecha; M A Connelly; A Admon; S P Lees-Miller; C W Anderson; S P Jackson
Journal:  Cell       Date:  1995-09-08       Impact factor: 41.582

3.  Antiinflammatory activity of the new mould metabolite 11-desacetoxy-wortmannin and of some of its derivatives.

Authors:  D Wiesinger; H U Gubler; W Haefliger; D Hauser
Journal:  Experientia       Date:  1974-02-15

4.  Nonradioactive methods for the assay of phosphoinositide 3-kinases and phosphoinositide phosphatases and selective detection of signaling lipids in cell and tissue extracts.

Authors:  Alexander Gray; Henric Olsson; Ian H Batty; Larisa Priganica; C Peter Downes
Journal:  Anal Biochem       Date:  2003-02-15       Impact factor: 3.365

5.  Wortmannin binds specifically to 1-phosphatidylinositol 3-kinase while inhibiting guanine nucleotide-binding protein-coupled receptor signaling in neutrophil leukocytes.

Authors:  M Thelen; M P Wymann; H Langen
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

6.  Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase.

Authors:  G Powis; R Bonjouklian; M M Berggren; A Gallegos; R Abraham; C Ashendel; L Zalkow; W F Matter; J Dodge; G Grindey
Journal:  Cancer Res       Date:  1994-05-01       Impact factor: 12.701

7.  Inhibition of the phagocytosis-induced respiratory burst by the fungal metabolite wortmannin and some analogues.

Authors:  M Baggiolini; B Dewald; J Schnyder; W Ruch; P H Cooper; T G Payne
Journal:  Exp Cell Res       Date:  1987-04       Impact factor: 3.905

8.  Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells.

Authors:  H Yano; S Nakanishi; K Kimura; N Hanai; Y Saitoh; Y Fukui; Y Nonomura; Y Matsuda
Journal:  J Biol Chem       Date:  1993-12-05       Impact factor: 5.157

9.  In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin.

Authors:  R M Schultz; R L Merriman; S L Andis; R Bonjouklian; G B Grindey; P G Rutherford; A Gallegos; K Massey; G Powis
Journal:  Anticancer Res       Date:  1995 Jul-Aug       Impact factor: 2.480

Review 10.  Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents.

Authors:  Stephen G Ward; Peter Finan
Journal:  Curr Opin Pharmacol       Date:  2003-08       Impact factor: 5.547

View more
  7 in total

Review 1.  The PI3K pathway as drug target in human cancer.

Authors:  Kevin D Courtney; Ryan B Corcoran; Jeffrey A Engelman
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

2.  A wortmannin-cetuximab as a double drug.

Authors:  R Adam Smith; Hushan Yuan; Ralph Weissleder; Lewis C Cantley; Lee Josephson
Journal:  Bioconjug Chem       Date:  2009-11       Impact factor: 4.774

3.  Abrogation of antibody-induced arthritis in mice by a self-activating viridin prodrug and association with impaired neutrophil and endothelial cell function.

Authors:  Lars Stangenberg; Chris Ellson; Virna Cortez-Retamozo; Adriana Ortiz-Lopez; Hushan Yuan; Joseph Blois; Ralph A Smith; Michael B Yaffe; Ralph Weissleder; Christophe Benoist; Diane Mathis; Lee Josephson; Umar Mahmood
Journal:  Arthritis Rheum       Date:  2009-08

4.  Real-time assessment of inflammation and treatment response in a mouse model of allergic airway inflammation.

Authors:  Virna Cortez-Retamozo; Filip K Swirski; Peter Waterman; Hushan Yuan; Jose Luiz Figueiredo; Andita P Newton; Rabi Upadhyay; Claudio Vinegoni; Rainer Kohler; Joseph Blois; Adam Smith; Matthias Nahrendorf; Lee Josephson; Ralph Weissleder; Mikael J Pittet
Journal:  J Clin Invest       Date:  2008-11-06       Impact factor: 14.808

5.  The antiproliferative cytostatic effects of a self-activating viridin prodrug.

Authors:  Adam Smith; Joseph Blois; Hushan Yuan; Elena Aikawa; Christian Ellson; Jose-Luiz Figueiredo; Ralph Weissleder; Rainer Kohler; Michael B Yaffe; Lewis C Cantley; Lee Josephson
Journal:  Mol Cancer Ther       Date:  2009-06-09       Impact factor: 6.261

6.  A stabilized demethoxyviridin derivative inhibits PI3 kinase.

Authors:  Hushan Yuan; Monica T Pupo; Joe Blois; Adam Smith; Ralph Weissleder; Jon Clardy; Lee Josephson
Journal:  Bioorg Med Chem Lett       Date:  2009-05-30       Impact factor: 2.823

7.  Theranostic Imaging of the Kinases and Proteases that Modulate Cell Death and Survival.

Authors:  Howard H Chen; Hushan Yuan; Lee Josephson; David E Sosnovik
Journal:  Theranostics       Date:  2012-02-08       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.